Illumina Inc. ($ILMN) Stock Forecast: Down 5.4% Today

What is Illumina Inc.?

Illumina (NASDAQ: ILMN) operates in the biotechnology sector, focusing on genetic sequencing and array-based technologies. With a strong market performance, the company has achieved an average annual return of 15.84% over the past twenty years.

Why is Illumina Inc. going down?

ILMN stock is down 5.4% on Apr 3, 2025 18:56

• Keith Meister joining Illumina's board suggests the possibility of strategic shifts or growth endeavors within the company.
• Although Illumina has historically performed well, recent market reactions may reflect concerns or uncertainties related to the influence of the new board member on future decisions.
• Investors may be hesitant about potential alterations in Illumina's direction under Meister's guidance, prompting a short-term sell-off of the company's stock.

ILMN Price Chart

ILMN Technical Analysis

ILMN News

Here's How Much $1000 Invested In Illumina 20 Years Ago Would Be Worth Today - Illumina ( NASDAQ:ILMN )

Illumina ILMN has outperformed the market over the past 20 years by 7.73% on an annualized basis producing an average annual return of 15.84%. Currently, Illumina has a market capitalization of $12.42 billion.

https://www.benzinga.com/insights/news/25/04/44598356/heres-how-much-1000-invested-in-illumina-20-years-ago-would-be-worth-today

Corvex's Meister joins the board at Illumina. Here's how he can create value for shareholders

Keith Meister, Corvex Management's chief investment officer, will join Illumina's board starting March 28. He's no stranger to the world of biotech.

https://www.cnbc.com/2025/03/29/corvexs-meister-joins-the-board-at-illumina-how-he-can-create-value.html

Trending Today

Tetra Tech Inc. ($TTEK) Stock Forecast: Up 5.7% Today

eBay Inc. ($EBAY) Stock Forecast: Up 5.5% Today

Shiba Inu ($SHIB) Crypto Forecast: Up 5.1% Today

Bitcoin ($BTC) Crypto Forecast: Up 5.2% Today

Novavax Inc. ($NVAX) Stock Forecast: Up 13.2% Today

GameStop Corp. ($GME) Stock Forecast: Up 5.2% Today

Amcor plc ($AMCR) Stock Forecast: Up 5.2% Today

MicroStrategy ($MSTR) Stock Forecast: Up 10.8% Today

Applied Materials Inc. ($AMAT) Stock Forecast: Up 6.1% Today

Vertex Pharmaceuticals Incorporated ($VRTX) Stock Forecast: Up 5.0% Today

Illumina Inc. Price History

23.00.2025 - ILMN Stock was down 5.5%

• Today, Illumina (ILMN) faced significant downward movement in the market, potentially due to the following factors:
• Positive earnings history and potential for surpassing estimates may have been overshadowed by shifting market sentiment linked to broader economic concerns or sector rotation.
• Cathie Wood's Ark Invest making notable trades involving various stocks while not increasing their investment in Illumina could have indicated waning confidence in the company.
• Investor response might be connected to uncertainties regarding Illumina's future growth opportunities or competitive pressures within the genomics sector.
• The bearish trend in Illumina's stock price today could have been influenced by overall market conditions and macroeconomic factors.

04.01.2025 - ILMN Stock was down 5.3%

• The decline in Illumina's stock today may be linked to China's decision to include ILMN in its 'Unreliable Entities List' amidst the current trade dispute with the US. This action introduces uncertainty and possible disruptions to Illumina's market activities.
• Initially, the market showed positive momentum in anticipation of Illumina's upcoming earnings report, which is expected to demonstrate growth. However, the impact of China's listing overshadowed this outlook, leading to the stock's decline.
• The market's response highlights investor concerns regarding the consequences of being on China's list and the broader effects of US-China trade tensions on Illumina's business operations and financial outcomes.

04.01.2025 - ILMN Stock was down 5.6%

• Illumina stock experienced a significant bearish movement recently.
• The decision to include Illumina in China's unreliable entities list, amidst trade war disruptions, likely influenced the stock's downward trend.
• Concerns regarding potential sanctions from the Chinese government following this listing may have unsettled investors, contributing to the bearish movement.
• Despite these challenges, analysts remain positive about Illumina's potential for earnings growth, offering a hopeful outlook for the stock's future.

05.02.2025 - ILMN Stock was up 5.3%

• Illumina stock experienced a strong bullish movement today.
• The stock might have surged due to the outperforming market performance over the past 20 years, with an average annual return of 17.25%.
• The drop in revenue from China and the ban on Illumina's gene sequencers might have initially caused a dip in the stock price, but investors seem to be focusing more on the long-term performance and growth potential of the company.
• Despite the short-term challenges, the positive long-term outlook and historical performance of Illumina could be driving the bullish movement in the stock today.

26.02.2025 - ILMN Stock was down 5.1%

• Today's decline in ILMN stock could be linked to:
• Completion of Illumina's AGD project sequenced 250,000 whole genomes, causing concerns about future growth and prompting investors to take profits.
• Ark Invest selling off Illumina shares, possibly leading other investors to follow suit after Cathie Wood's fund reduced its position in the company.
• Shifting market sentiment towards biotech stocks with investors redirecting investments to companies such as Iridium, Beam, and Pacific Biosciences, which were favored by Ark Invest over Illumina.

16.00.2025 - ILMN Stock was down 5.4%

• Despite partnering with NVIDIA for genomic advancements and raising its Q4 revenue outlook, Illumina's stock experienced a bearish movement.
• The market may have reacted negatively due to concerns about the company's full-year revenue projection being down 2% YoY, despite exceeding street expectations for Q4 revenue.
• Additionally, Cathie Wood's Ark Invest loading up on Intellia Therapeutics and making significant trades in other companies, including Illumina, might have influenced market sentiment towards Illumina's stock negatively.
• Investors could be interpreting the layoffs at Intellia Therapeutics, one of the companies Ark Invest invested in, as a sign of potential challenges in the genomics sector, leading to a bearish movement in Illumina's stock.

03.03.2025 - ILMN Stock was down 5.4%

• Keith Meister joining Illumina's board suggests the possibility of strategic shifts or growth endeavors within the company.
• Although Illumina has historically performed well, recent market reactions may reflect concerns or uncertainties related to the influence of the new board member on future decisions.
• Investors may be hesitant about potential alterations in Illumina's direction under Meister's guidance, prompting a short-term sell-off of the company's stock.

12.02.2025 - ILMN Stock was down 6.5%

• Plans to cut $100 million in costs by 2025 due to China trade restrictions impacting a significant portion of its sales have led to a lowered profit outlook. This news likely contributed to the bearish movement in the stock.
• The decision to lower its 2025 adjusted EPS guidance to $4.50, at the lower end of the range, reflects the challenges faced in the current trade environment.
• Despite some unusual bullish options activity noted by investors, the overall sentiment towards Illumina seems to have been overshadowed by the negative impact of the trade tensions and cost-cutting measures.

07.01.2025 - ILMN Stock was down 10.3%

• Illumina (ILMN) fell short of Q4 earnings expectations, impacting investor sentiment negatively.
• Concerns emerged over the company's placement on China's unreliable entities list and the potential impact on its operations.
• Recent geopolitical tensions and earnings missing estimates have played a role in the stock's downturn despite its historical market outperformance.
• The broader market volatility and global trade relations uncertainties have potentially intensified the selling pressure on Illumina shares.

27.01.2025 - ILMN Stock was down 6.3%

• Despite Illumina's strong track record and partnerships within the biotech industry, its stock showed bearish trends in the market.
• The stock's decline could be attributed to various economic conditions or industry-specific updates affecting biotech stocks.
• Investors might be capitalizing on previous gains, causing a temporary decrease in the stock value.
• Monitoring Illumina's collaborations and technological progress will be crucial in predicting its future market performance.

07.01.2025 - ILMN Stock was down 9.1%

• Illumina's Q4 earnings fell short of estimates, causing a decrease in the stock price and raising concerns among investors about the company's performance.
• The company's inclusion on China's unreliable entities list added more pressure on the stock, creating uncertainties about its future operations and growth in a significant market.
• Despite the recent decline, Illumina's strong historical market performance over the past two decades highlights its track record and potential for long-term growth, making it an appealing option for investors seeking stability in the genomics sector.

20.01.2025 - ILMN Stock was up 5.4%

• ILMN stock experienced a bullish movement likely due to being highlighted alongside other healthcare stocks leveraging AI advancements for innovation.
• The mention of ILMN in discussions about companies driving advancements in genomics and clinical research could have sparked investor interest and confidence in the company's future prospects.
• The positive sentiment surrounding AI advancements in healthcare, coupled with ILMN's position in the genomics industry, likely contributed to the strong bullish movement in the stock today.